Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05975099 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 807
- Enrollment target
NCT05975099 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 807 participants.
The verdict
NCT05975099, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 807 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1975
- BIOLOGICAL mRNA-1982
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 807 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05975099
The ClinicalTrials.gov registry entry for NCT05975099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 807 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05975099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05975099 about?
NCT05975099 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age". The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
What is the current status of trial NCT05975099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 807 participants. The study started on 2023-07-26. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05975099?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1975 (BIOLOGICAL), mRNA-1982 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05975099?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.